HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

<p>42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line setting—doubling historical ORR reported with pembrolizumab alone1 Strong immunogenicity and activation of antigen-specific CD8+ T cells observed Data reinforce HOOKIPA’s commitment to start a randomized trial of HB-200 in combination with pembrolizumab as 1st-line […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/hookipa-pharma-presents-additional-preliminary-phase-2-data-on-hb-200-in-combination-with-pembrolizumab-as-first-line-treatment-in-patients-with-hpv16-head-and-neck-cancers-at-european-society-for-me/">HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>